China has more prevalent cases of pancreatic cancer (103,000 vs. 66,000), but lower age-standardized rates, compared to the US. The US has higher age-standardized rates of incidence, mortality, and disability-adjusted life years (DALYs), attributed to high fasting plasma glucose being the leading risk factor
A University of Oklahoma researcher is investigating how a diet high in saturated fats may contribute to tumor growth by weakening the immune response and changing how cancer cells use fats. The study aims to understand the interaction between diet, obesity, immune function, and tumor metabolism in pancreatic cancer.
The program will use AI-driven risk assessment, next-generation DNA testing, and personalized surveillance to identify pancreatic cancer at its earliest stages. It will also leverage world-class imaging technologies and expand access to specialized screening and prevention services.
Researchers have identified complement factor B as a promising target for pancreatic cancer treatment. Inhibiting this enzyme suppresses cancer growth, induces cellular senescence, and remodels the tumor immune microenvironment. The combination of CFB inhibition with chemotherapy and immunotherapy showed the greatest tumor suppression.
Researchers at ICABS 2026 explored personalized cancer vaccines, T-cell therapy, and treatment resistance. Key findings included the development of neoantigen-based vaccines and immune cell metabolism, as well as strategies targeting tumor vulnerabilities.
Researchers found distinct molecular signatures in pancreatic cancer cells from Black African Americans and Non-African Americans, highlighting potential differences in treatment responses. The study also discovered variations in immune cell populations within tumor microenvironments, which may impact cancer outcomes.
Researchers have discovered how reprogrammed cancer cells can promote the formation of immune cells clusters that help coordinate the immune response, leading to better treatment outcomes for patients. The study's findings suggest that cell reprogramming could become a way to make tumors more responsive to immunotherapy.
Fox Chase Cancer Center researchers have identified a potential new target for pancreatic cancer by blocking a protein called ANO6. ANO6 helps pancreatic cancer cells obtain nutrients from surrounding cells while suppressing the immune system's ability to fight tumors.
A new analysis of a phase 3 clinical trial found that daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer. The treatment consistently provided a benefit regardless of tumor RAS mutation status or previous treatment history.
A new vaccine has shown promise in generating an immune response against KRAS mutations in pancreatic cancer, with patients who developed stronger immune responses showing longer disease-free survival. The vaccine targets seven common KRAS mutations and has the potential to improve treatment outcomes for patients with pancreatic cancer.
A Mayo Clinic study found that patients with pancreatic cancer experience steeper declines in visceral and subcutaneous fat before diagnosis compared to controls. Routine CT scans may capture these physiological changes, potentially identifying patients at risk
Researchers analyzed nearly half a million cells from dozens of patients' tumors to understand how pancreatic cancer cells continuously evolve over time. The study found that specific genetic changes, such as increased activity of the MYC gene, enable cancer cells to resist therapy and spread rapidly.
A new analysis of nearly half a million cells from dozens of pancreatic tumors reveals how tumor evolution, subtype transitions, and microenvironment interactions shape the disease. Genetic reconfiguration within a tumor enables cancer cells to transition between subtypes, making them more vulnerable to immune attack.
The FDA has approved daraxonrasib, a targeted therapy, based on a global clinical trial. Patients who took daraxonrasib lived almost twice as long as those receiving chemotherapy. Meanwhile, a grant from the Pancreatic Cancer Action Network aims to establish a blood test for pancreatic cancer using circulating tumor DNA.
A new device has been approved for a first human trial to treat cancer-related wasting, a severe and progressive syndrome affecting many patients with advanced cancer. The device, OnVagus, delivers noninvasive electrical stimulation to modulate the vagus nerve, aiming to preserve strength and quality of life during treatment.
A new study finds that high fasting glucose has surpassed tobacco use as the leading risk factor for pancreatic cancer in the US, while China faces a dual metabolic-tobacco burden. China recorded more absolute cases, but lower age-standardized rates, with a peak burden at ages 60-74.
Researchers have identified three subclusters of cells driving pancreatic cancer-induced cachexia, a muscle-wasting and fat-loss condition that affects pancreatic cancer patients. The subclusters form a triangular regulatory network that drives the initiation and progression of cachexia.
A randomized phase 2 trial found that five treatments of stereotactic body radiation therapy (SBRT) better preserved physical function and reduced fatigue compared to 28 treatments of conventional radiation therapy with chemotherapy. Rates of cancer remaining in lymph nodes did not differ significantly between the groups.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
A regulator-mandated study found no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden, and Norway. The study, funded by Novo, included over 97,000 semaglutide users and compared them to users of other non-incretin antidiabetic drugs.
A Chinese registry report presents real-world perioperative and survival outcomes for surgically treated pancreatic cancer patients, achieving high overall survival rates and encouraging surgical safety metrics. The study emphasizes the need for national-level benchmarks and standardized clinical protocols for pancreatic surgery in China.
Researchers developed an AI model that accurately predicted pancreatic cancer risk three years before diagnosis, using a patient's comprehensive health history and routine laboratory tests. The model achieved high accuracy in distinguishing between at-risk and low-risk individuals, with an AUROC of 0.853.
A new, incisionless liver cancer treatment called histotripsy was associated with low rates of laboratory toxicity and procedural complications in a real-world review of 972 patients. However, the study found that 11% of patients died within 30 days, suggesting that advanced cancer and overall disease burden may be contributing factors.
A new blood test, PANXEON, detects stage 1 and 2 pancreatic cancer with high sensitivity and low false-positive rates, identifying high-grade dysplasia with 64% accuracy. The test could enable early intervention and improve treatment options for patients with inherited risk or family history of pancreatic cancer.
Daraxonrasib, a novel RAS-targeted therapy, has been approved for adults with metastatic pancreatic adenocarcinoma. Clinical trials have shown a median overall survival of 13.2 months and nearly three times the objective response rate compared to chemotherapy. The medication targets KRAS, NRAS, and HRAS mutations, covering over 90% of ...
Researchers found that spatial patterns in pathology slides can identify patients at greater risk of pancreatic cancer recurrence after treatment. AI-enabled analysis measured tissue shape, fragmentation, and cancer-stroma intermixing to predict disease-free survival.
A new device uses electricity to separate cancer-associated signals from healthy particles in the blood, offering a new method for studying pancreatic cancer. The device, which sorts particles based on their electrical charge, showed promise in distinguishing cancer samples from healthy ones.
Researchers found that pancreatic cancer cells create localized immune-protective niches that shield tumors from immune attack. Disrupting these protective mechanisms slowed tumor growth and improved responses to immunotherapy in preclinical models.
Massey researchers will evaluate TROP2 targeted ADCs for breast and pancreatic cancer care, aiming to identify predictive biomarkers and therapeutic strategies. The grant will help develop a test to predict patient drug response and identify secondary treatments for resistant tumors.
Daraxonrasib, the first approved RAS-targeted therapy, nearly doubles median overall survival in metastatic pancreatic cancer patients, with a 60% reduced risk of death. The phase 3 RASolute 302 trial showed substantial improvement in overall survival and cancer progression compared to chemotherapy.
Researchers have developed an mRNA immunotherapy that eliminates pancreatic tumors in mice, achieving complete tumor responses and long-term disease-free periods. The treatment uses a cocktail of immune cytokine and tumor-associated antigen mRNAs, showing promise as a potential transformative treatment for pancreatic cancer.
Researchers at Purdue University have developed L-32, a quinolone-based inhibitor that targets PTPN22, a negative regulator of the immune system. This compound promotes robust antitumor immunity and has improved potency, selectivity, and cellular efficacy compared to previous derivatives.
Researchers estimated cancer risk in patients with pancreatic cysts with worrisome or high-risk features, finding that risk increased with the number of worrisome features. The study suggests that regular surveillance may be an appropriate approach for some patients rather than immediate surgery.
The updated guideline provides evidence-based recommendations on radiation therapy for adult patients with pancreatic cancer, clarifying its role in various settings. It recommends radiation therapy for patients with resectable, locally advanced, and metastatic disease, as well as those with recurrent or palliative needs.
Researchers developed a new approach called SHIFTERS that uses focused ultrasound to temporarily 'light up' solid tumors, giving cancer-fighting immune cells a target they can recognize. The technology allows doctors to control where and when treatment switches on, potentially making solid tumors easier to treat.
Researchers identify AGR2 as a prognostic marker for NF-PanNETs, while FOXM1 is found to promote malignancy and proliferation. AGR2-high cells exhibit malignant features, including increased proliferative activity and metastasis-like signatures.
Researchers at USC have developed a genetic tool called the Mechano-Recorder to measure tumor cell softness. This insight can help target hard-to-reach cancer stem-like cells for destruction, potentially improving cancer treatment outcomes.
Scientists at Cancer Research UK Scotland Institute and University of Glasgow identify a new pathway for delivering antisense oligonucleotides (ASOs) into cells, enhancing the effectiveness of ASO-based therapy for pancreatic cancer and other diseases. The researchers found that ASOs enter cells via endocytosis and bind to specific rec...
A Rutgers Cancer Institute physician-scientist says a VA study comparing two hormone therapies for metastatic prostate cancer provides strong real-world evidence to help doctors choose the right drug for each patient. The study found that enzalutamide may offer a modest survival advantage for patients aged 75 and older.
A University of Oklahoma researcher is receiving a five-year, $2 million NCI grant to investigate how pancreatic cancer uses cholesterol to survive chemotherapy. The research aims to identify new ways to treat this deadliest form of cancer by uncovering the biological processes that help tumors thrive.
Researchers developed an experimental drug using AI to target a 'undruggable' protein in pancreatic cancer, slowing tumor growth and improving survival rates. The study demonstrates the potential for AI-assisted discovery of new cancer treatments.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
Researchers at the University of Chicago report a promising new strategy using BifidoSumIL-2, an engineered bacterial strain, to deliver an immune-stimulating therapy directly into pancreatic tumors. The treatment selectively activates cancer-fighting T cells and slows tumor growth, even when combined with chemotherapy or radiotherapy.
University of Minnesota researchers found that certain immune cells, regulatory T cells, prevent helpful T cells from eliminating hidden cancer cells. By combining treatment strategies, they improved the immune response and reduced cancer spread in preclinical models.
The IRP1/ARID3A complex suppresses ferroptosis and promotes chemoresistance in pancreatic cancer by epigenetically silencing cytoglobin (CYGB). Restoration of CYGB expression reverses these effects, sensitizing tumor cells to ferroptosis and improving treatment outcomes.
A vaccine targeting KRAS mutations was safe and stimulated durable immune responses in high-risk individuals. After a median follow-up of 16.5 months, none of the participants developed pancreatic cancer, and some precancerous lesions shrank or stopped growing.
Sylvester researchers develop AI-powered fracture prediction models, train as wildland firefighters to reduce cancer risk, and discover new targets for pancreatic cancer treatment. A new tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells.
Researchers developed nanoparticles that retain their protective coating in normal tissue but shed it upon reaching tumor tissue, releasing anticancer drugs. This technology reduces systemic side effects and enhances treatment efficacy.
A new preclinical study has identified a gut bacterium, Akkermansia muciniphila, that helps prime intestinal stem cells for faster recovery after radiation treatment. Fasting increases the population of this bacterium, which produces a small molecule that changes histone tags to allow gene expression in intestinal cells.
Researchers have developed a microfluidic platform that recreates the complex ecosystem surrounding pancreatic tumors and observed how cells interact dynamically. The findings reveal a critical mechanism that may explain why many therapies fail and point to new therapeutic strategies.
A Phase I/II study showed high tumor shrinkage and substantial reductions in cancer DNA detected in the bloodstream. The treatment combination of zoldonrasib with chemotherapy improved patient outcomes, suggesting a potential breakthrough in personalized treatment for pancreatic cancer.
Researchers have uncovered a potential strategy to eliminate cancer cells that survive KRAS inhibition, preventing relapse. By targeting the metabolic pathways that support the survival of drug-tolerant persister cells, treatment regimens could be designed to shrink tumors and prevent cancer recurrence.
A multidisciplinary panel of experts recommends evidence-based screening and surveillance strategies for pancreatic cancer in high-risk populations, aiming to improve early diagnosis and survival. The guidelines specify starting ages, surveillance intervals, imaging modalities, surgical indications, and lifestyle modifications.
Researchers at Salk Institute uncover an unexpected role for HDAC enzymes in controlling critical genes involved in DNA repair, making pancreatic cells more vulnerable to therapies that induce DNA damage. This finding paves the way for new treatment strategies combining entinostat with DNA-damaging therapies.
Pre-retrieval imaging is revolutionizing liver transplantation by improving graft selection, reducing uncertainty, and supporting better surgical planning. Imaging modalities like ultrasound, CT, and MRI offer distinct strengths and limitations in evaluating liver graft quality, vascular anatomy, and biliary variants.
Researchers have identified IL1RAP as a key player in the tumor-driven inflammatory network that helps pancreatic cancer resist treatment. Blocking this receptor may help break down tumors and improve response to combination therapy.
A team of researchers has identified a previously unknown vulnerability in KRAS-mutated pancreatic cancer cells, making them susceptible to necroptosis. Blocking the tumor cells' defense mechanism by inhibiting caspase-8 leads to significant cell death and reduced tumor growth.
Scientists at VUB mapped healthy pancreas cells down to the cellular level, discovering rare cells with properties similar to aggressive tumour cells. This fundamental discovery may offer opportunities for early detection of pancreatic cancer, currently one of the most difficult diseases to treat.
Researchers investigated polyisoprenylated cysteinyl amide inhibitors (PCAIs) for their anticancer effects on pancreatic cancer cells with KRAS mutations. The compounds demonstrated strong activity against cell survival, migration, and invasion pathways. PCAI treatment caused hyperactivation of MAPK and PI3K/AKT pathways, leading to ox...
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.